Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Teladoc operates in two business segments - Teladoc Health Integrated Care and BetterHelp. Integrated Care consists of B2B distribution channels, including services offered through employers, health plans, and other providers. BetterHelp consists of mental health services sold through direct-to-consumer distribution channels. Teladoc Health Inc., based in Purchase, New York, provides telemedicine virtual healthcare services in the United States and internationally. Customers can speak to licensed physicians about non-emergency care, mental health, and dermatological conditions, and receive remote prescriptions for medication. Clients sign up for yearly or monthly subscriptions, and may also pay a flat fee for an appointment. Founded in 2002, the company has grown into one of the largest virtual healthcare platforms in the United States. Since its IPO in 2015, the company has increased its membership, product offerings, and the utilization of its services.

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Teladoc Health Inc., based in Purchase, New York, provides telemedicine virtual healthcare services in the United States and internationally. Customers can speak to licensed physicians about non-emergency care, mental health, and dermatological conditions, and receive remote prescriptions for medication. Clients sign up for yearly or monthly subscriptions, and may also pay a flat fee for an appointment. Founded in 2002, the company has grown into one of the largest virtual healthcare platforms in the United States. Since its IPO in 2015, the company has increased its membership, product offerings, and the utilization of its services.